Payment overview · 2025
General Payments
$502.40
24 reported records · 10 companies
Healthcare provider profile · identity verified
Darrell Robert Mease, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · JAY, OK · NPI 1952377442
Verified facts
What the public records show
CMS Open Payments records show Darrell Robert Mease, M.D. received $502.40 in general payments during 2025 across 24 reported records.
Amgen Inc. accounted for 39.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 12 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Gemtesa, Mounjaro, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARMOUR THYROID as an associated drug or biological on 50 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Armour Thyroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 81 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Vraylar by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 100 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 93 claims for Trulicity by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $195.97 | 39.0% | 9 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $84.97 | 16.9% | 4 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $70.59 | 14.1% | 4 | 2025 |
| SK Life Science, Inc. |
SK Life Science, Inc. exact · evidence 2025-04-03 |
$32.03 | 6.4% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $23.53 | 4.7% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $22.91 | 4.6% | 1 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $21.73 | 4.3% | 1 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$21.11 | 4.2% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $16.10 | 3.2% | 1 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $13.46 | 2.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $502.40 | 24 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $195.97 | 9 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $133.77 | 6 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $84.97 | 4 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $41.22 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $29.37 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $23.53 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $22.91 | 1 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $21.73 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $21.58 | 1 | 2025 |
Source payment records
|
|||||
| INTERSTIM Normalized: interstim |
Device | Medtronic, Inc. | $21.11 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $16.10 | 1 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $13.46 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 100 | exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 25 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | ARMOUR THYROID open payments reported associated product |
CMS Open Payments — General Payments 50 supporting records · 11 recipient NPIs · example record 1201517088 |
Armour Thyroid · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
81 | 20 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
48 | 12 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
100 | 21 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
93 | 16 |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 614 | 143 |
| Levothyroxine Sodium | Levothyroxine Sodium | 603 | 107 |
| Pantoprazole Sodium | Pantoprazole Sodium | 445 | 94 |
| Omeprazole | Omeprazole | 423 | 93 |
| Baclofen | Baclofen | 411 | 92 |
| Topiramate | Topiramate | 391 | 84 |
| Spironolactone | Spironolactone | 389 | 94 |
| Gabapentin | Gabapentin | 363 | 87 |
| Furosemide | Furosemide | 341 | 73 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 338 | 88 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 330 | 112 |
| Lisinopril | Lisinopril | 324 | 71 |
| Metoprolol Tartrate | Metoprolol Tartrate | 286 | 59 |
| Trazodone Hcl | Trazodone Hcl | 283 | 54 |
| Amlodipine Besylate | Amlodipine Besylate | 274 | 62 |
| Fluoxetine Hcl | Fluoxetine Hcl | 273 | 49 |
| Liothyronine Sodium | Liothyronine Sodium | 265 | 66 |
| Tamsulosin Hcl | Tamsulosin Hcl | 258 | 51 |
| Losartan Potassium | Losartan Potassium | 250 | 65 |
| Escitalopram Oxalate | Escitalopram Oxalate | 243 | 47 |
| Famotidine | Famotidine | 242 | 56 |
| Eliquis | Apixaban | 222 | 37 |
| Finasteride | Finasteride | 182 | 30 |
| Metformin Hcl | Metformin Hcl | 179 | 46 |
| Tramadol Hcl | Tramadol Hcl | 171 | 46 |
| Metoprolol Succinate | Metoprolol Succinate | 170 | 35 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 169 | 35 |
| Clopidogrel | Clopidogrel Bisulfate | 168 | 42 |
| Simvastatin | Simvastatin | 161 | 27 |
| Levetiracetam | Levetiracetam | 157 | 19 |
| Potassium Chloride | Potassium Chloride | 156 | 34 |
| Quetiapine Fumarate | Quetiapine Fumarate | 152 | 35 |
| Ezetimibe | Ezetimibe | 147 | 25 |
| Diclofenac Sodium | Diclofenac Sodium | 138 | 39 |
| Fluticasone Propionate | Fluticasone Propionate | 133 | 51 |
| Ozempic | Semaglutide | 133 | 27 |
| Carvedilol | Carvedilol | 132 | 24 |
| Cefdinir | Cefdinir | 131 | 83 |
| Metformin Hcl Er | Metformin Hcl | 126 | 34 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 125 | 37 |
| Sertraline Hcl | Sertraline Hcl | 125 | 26 |
| Meloxicam | Meloxicam | 124 | 35 |
| Hydrochlorothiazide | Hydrochlorothiazide | 123 | 31 |
| Pioglitazone Hcl | Pioglitazone Hcl | 123 | 33 |
| Allopurinol | Allopurinol | 116 | 24 |
| Aripiprazole | Aripiprazole | 116 | 17 |
| Prednisone | Prednisone | 116 | 73 |
| Memantine Hcl | Memantine Hcl | 112 | 25 |
| Montelukast Sodium | Montelukast Sodium | 106 | 21 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 105 | 23 |
| Symbicort | Budesonide/Formoterol Fumarate | 102 | 28 |
| Mounjaro | Tirzepatide | 100 | 21 |
| Duloxetine Hcl | Duloxetine Hcl | 99 | 19 |
| Doxycycline Hyclate | Doxycycline Hyclate | 97 | 67 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 96 | 23 |
| Metoclopramide Hcl | Metoclopramide Hcl | 96 | 24 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 96 | 23 |
| Trulicity | Dulaglutide | 93 | 16 |
| Buspirone Hcl | Buspirone Hcl | 92 | 13 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 89 | 26 |
| Doxazosin Mesylate | Doxazosin Mesylate | 88 | 19 |
| Alprazolam | Alprazolam | 86 | 25 |
| Np Thyroid | Thyroid,pork | 86 | 16 |
| Citalopram Hbr | Citalopram Hydrobromide | 84 | 18 |
| Celecoxib | Celecoxib | 83 | 18 |
| Naproxen | Naproxen | 82 | 21 |
| Linzess | Linaclotide | 81 | 20 |
| Metolazone | Metolazone | 81 | 16 |
| Mometasone Furoate | Mometasone Furoate | 81 | 44 |
| Tizanidine Hcl | Tizanidine Hcl | 78 | 18 |
| Valsartan | Valsartan | 75 | 16 |
| Terazosin Hcl | Terazosin Hcl | 74 | 15 |
| Testosterone Cypionate | Testosterone Cypionate | 74 | 26 |
| Azithromycin | Azithromycin | 73 | 56 |
| Ondansetron Odt | Ondansetron | 72 | 37 |
| Xarelto | Rivaroxaban | 70 | 14 |
| Oxcarbazepine | Oxcarbazepine | 66 | suppressed |
| Glipizide | Glipizide | 63 | 16 |
| Lamotrigine | Lamotrigine | 62 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 62 | 12 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 61 | 15 |
| Bupropion Hcl Sr | Bupropion Hcl | 60 | 12 |
| Dexlansoprazole Dr | Dexlansoprazole | 60 | 13 |
| Nebivolol Hcl | Nebivolol Hcl | 59 | 13 |
| Amitriptyline Hcl | Amitriptyline Hcl | 58 | 11 |
| Dicyclomine Hcl | Dicyclomine Hcl | 58 | 18 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 58 | 12 |
| Anastrozole | Anastrozole | 56 | 13 |
| Benazepril Hcl | Benazepril Hcl | 55 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 55 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 54 | 16 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 54 | 32 |
| Ramipril | Ramipril | 54 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 53 | suppressed |
| Myrbetriq | Mirabegron | 53 | 11 |
| Donepezil Hcl | Donepezil Hcl | 52 | 11 |
| Januvia | Sitagliptin Phosphate | 49 | 12 |
| Methotrexate | Methotrexate Sodium | 49 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 49 | 12 |
| Jardiance | Empagliflozin | 48 | 12 |
| Progesterone | Progesterone, Micronized | 48 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 48 | 41 |
| Cephalexin | Cephalexin | 46 | 38 |
| Fluconazole | Fluconazole | 46 | 29 |
| Ropinirole Hcl | Ropinirole Hcl | 46 | 11 |
| Diazepam | Diazepam | 45 | suppressed |
| Estradiol | Estradiol | 45 | suppressed |
| Risperidone | Risperidone | 44 | suppressed |
| Bupropion Xl | Bupropion Hcl | 42 | suppressed |
| Digoxin | Digoxin | 42 | suppressed |
| Rexulti | Brexpiprazole | 41 | suppressed |
| Sucralfate | Sucralfate | 41 | suppressed |
| Sulindac | Sulindac | 40 | 12 |
| Trintellix | Vortioxetine Hydrobromide | 40 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 38 | suppressed |
| Diclofenac Potassium | Diclofenac Potassium | 38 | 12 |
| Ipratropium Bromide | Ipratropium Bromide | 38 | 21 |
| Pravastatin Sodium | Pravastatin Sodium | 38 | suppressed |
| Pregabalin | Pregabalin | 38 | suppressed |
| Clonazepam | Clonazepam | 37 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 37 | suppressed |
| Ketoconazole | Ketoconazole | 36 | 16 |
| Lidocaine | Lidocaine | 36 | suppressed |
| Primidone | Primidone | 36 | suppressed |
| Entresto | Sacubitril/Valsartan | 35 | suppressed |
| Eszopiclone | Eszopiclone | 35 | 12 |
| Rivastigmine | Rivastigmine | 35 | suppressed |
| Dexamethasone | Dexamethasone | 34 | 31 |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 34 | suppressed |
| Olanzapine | Olanzapine | 34 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 34 | suppressed |
| Armour Thyroid | Thyroid,pork | 32 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 32 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 32 | 15 |
| Lurasidone Hcl | Lurasidone Hcl | 32 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 32 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 31 | suppressed |
| Repatha Sureclick | Evolocumab | 31 | suppressed |
| Repatha Syringe | Evolocumab | 31 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 31 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 29 | 29 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 28 | 26 |
| Bupropion Hcl | Bupropion Hcl | 28 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 28 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 28 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 28 | suppressed |
| Mirtazapine | Mirtazapine | 28 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 28 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 28 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 27 | suppressed |
| Naltrexone Hcl | Naltrexone Hcl | 27 | suppressed |
| Atenolol | Atenolol | 26 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 26 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 26 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 25 | suppressed |
| Vraylar | Cariprazine Hcl | 25 | suppressed |
| Ibuprofen | Ibuprofen | 23 | suppressed |
| Roflumilast | Roflumilast | 23 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 23 | suppressed |
| Gemfibrozil | Gemfibrozil | 22 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 22 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 22 | suppressed |
| Bumetanide | Bumetanide | 21 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 21 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 21 | suppressed |
| Levemir Flexpen | Insulin Detemir | 21 | suppressed |
| Lorazepam | Lorazepam | 21 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 21 | 12 |
| Atomoxetine Hcl | Atomoxetine Hcl | 20 | suppressed |
| Calcium Acetate | Calcium Acetate | 20 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 20 | suppressed |
| Nabumetone | Nabumetone | 20 | suppressed |
| Nystatin | Nystatin | 20 | 12 |
| Pentoxifylline | Pentoxifylline | 20 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 20 | suppressed |
| Constulose | Lactulose | 19 | suppressed |
| Desmopressin Acetate | Desmopressin Acetate | 19 | suppressed |
| Dulera | Mometasone/Formoterol | 19 | suppressed |
| Gemtesa | Vibegron | 19 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 19 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 19 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 19 | suppressed |
| Tobramycin | Tobramycin | 19 | 11 |
| Chlorthalidone | Chlorthalidone | 18 | suppressed |
| Fycompa | Perampanel | 18 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 18 | suppressed |
| Lubiprostone | Lubiprostone | 18 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 18 | suppressed |
| Topiramate Er | Topiramate | 18 | suppressed |
| Trijardy Xr | Empaglifloz/Linaglip/Metformin | 18 | suppressed |
| Acyclovir | Acyclovir | 17 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 17 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 17 | suppressed |
| Glipizide Er | Glipizide | 17 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 16 | suppressed |
| Methimazole | Methimazole | 16 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 16 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 16 | suppressed |
| Ciclopirox | Ciclopirox | 15 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 15 | 14 |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 15 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 15 | suppressed |
| Nitroglycerin | Nitroglycerin | 15 | suppressed |
| Lactulose | Lactulose | 14 | suppressed |
| Leflunomide | Leflunomide | 14 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 13 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 13 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Ciprofloxacin-Dexamethasone | Ciprofloxacin Hcl/Dexameth | 13 | suppressed |
| Folic Acid | Folic Acid | 13 | suppressed |
| Gentamicin Sulfate | Gentamicin Sulfate | 13 | suppressed |
| Guanfacine Hcl | Guanfacine Hcl | 13 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 13 | suppressed |
| Lidocaine-Prilocaine | Lidocaine/Prilocaine | 13 | 12 |
| Metronidazole | Metronidazole | 13 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 13 | suppressed |
| Vascepa | Icosapent Ethyl | 13 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Brilinta | Ticagrelor | 12 | suppressed |
| Cimetidine | Cimetidine | 12 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 12 | suppressed |
| Enbrel Sureclick | Etanercept | 12 | suppressed |
| Fenofibrate | Fenofibrate | 12 | suppressed |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 12 | suppressed |
| Lacosamide | Lacosamide | 12 | suppressed |
| Levofloxacin | Levofloxacin | 12 | 11 |
| Methocarbamol | Methocarbamol | 12 | suppressed |
| Minocycline Hcl | Minocycline Hcl | 12 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 12 | suppressed |
| Xeljanz Xr | Tofacitinib Citrate | 12 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 11 | suppressed |
| Glimepiride | Glimepiride | 11 | suppressed |
| Hydrocortisone | Hydrocortisone | 11 | suppressed |
| Levemir | Insulin Detemir | 11 | suppressed |
| Novolog Flexpen | Insulin Aspart | 11 | suppressed |
| Praluent Pen | Alirocumab | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $502.40 · 24 records | Amgen Inc. | Auvelity, Cologuard Collection Kit, FANAPT, GEMTESA, INTERSTIM, MOUNJARO, OTEZLA, QULIPTA, REPATHA, UBRELVY, VRAYLAR, YUPELRI | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Gemtesa play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error